AstraZeneca, breast cancer
AstraZeneca's experimental drug disappoints in breast cancer survival trial
AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer in a late-stage trial.
AstraZeneca drug fails to extend lives of breast cancer patients
A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ambitions to hit an $80bn revenue target by 2030.
Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients
AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically significant improvement in overall survival. The trial met its progression-free survival endpoint,
AstraZeneca's experimental cancer drug shows no significant improvement in overall survival
AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer in a late-stage trial.
AstraZeneca and Daiichi Suffer New Setback With Mixed Breast Cancer Drug Results
AstraZeneca Plc said an experimental cancer drug it’s developing with Daiichi Sankyo Co. did not help breast cancer patients live longer than chemotherapy.
AstraZeneca Stock Dips On Surprise Miss For Gilead-Rivaling Cancer Drug
AstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast cancer.
AstraZeneca and Daiichi Sankyo report data from Phase III breast cancer trial
AstraZeneca and Daiichi Sankyo have reported results from the TROPION-Breast01 Phase III clinical trial of datopotamab deruxtecan (Dato-DXd) for breast cancer. The trial compared Dato-DXd to the investigator's choice of chemotherapy in patients with inoperable or metastatic hormone receptor (HR)-positive,
AARP6d
Rx Drug Law Saves Some Cancer Patients More Than $7,000 in 2024
A recent survey from AARP found that roughly 40 percent of adults age 65-plus who are eligible for Medicare have either ...
AstraZeneca Pharma receives nod for cancer drug Durvalumab; stock soars 12%
The uptick in AstraZeneca share price came after the company announced that it has received permission to import for sale and ...
devdiscourse4h
Top Health News: Drug Trials, Bird Flu, and Mpox Updates
This summary covers various health news briefs including AstraZeneca's breast cancer drug trial results, a bird flu case in ...
Pfizer: Potential cachexia cancer drug shows life-saving promise
A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical ...
Science Daily2d
Cancer News
Clinical Trial Successfully Repurposes Cancer Drug for Hereditary Bleeding Disorder Sep. 18, 2024 — A drug approved for treating the blood cancer multiple myeloma may offer a safe and ...
News Medical7m
Using cell painting for image-based phenotypic profiling in 3D spheroid model of breast cancer
This article from Molecular Devices explores how cell painting can be used in a 3D breast cancer spheroid model for ...
FDA expands approval for drug to treat early-stage breast cancer
The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat ...
Medscape3d
Europe Recommends Lung Cancer Drug Hetronifly
Hetronifly in combination with chemotherapy was shown to improve survival of patients with extensive stage small cell lung ...
Chemicals linked to breast cancer leach into our foods, study finds
Nearly 200 chemicals connected to breast cancer are used in the making of food packaging and plastic tableware, and dozens of ...